Quest diagnostics introduces hpv specimen self-collection for cervical cancer screening

Providers in the united states may now order the fda-cleared hpv self-collection solution for their patients to use in their offices or other healthcare settings, with goal to reduce barriers to screening by enabling discreet self-collection quest also plans to make self-collection option available at its 2,000 patient service centers in the united states early next month, expanding access to screening new solution follows company's launch of gti self-collection option for several stis and related conditions last fall secaucus, n.j. , april 2, 2025 /prnewswire/ -- quest diagnostics (nyse: dgx), a leader in diagnostic information services, today announced a new solution aimed at broadening access to human papillomavirus (hpv) screening to help identify women who are at risk of developing cervical cancer.
DGX Ratings Summary
DGX Quant Ranking